Informations générales (source: ClinicalTrials.gov)
Evaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology
Observational
ZIWIG (Voir sur ClinicalTrials)
décembre 2024
décembre 2026
13 septembre 2025
GynRAN is an international, multicentre, transversal, diagnostic and non-interventional
study carried out in gynecology-obstetrics/gynecological oncology departments that aims
to identify a diagnostic signature for gynecological pathologies by analyzing of coding
and non-coding RNA contained in patients saliva.
The study population consists of patients with clinically symptomatic females with one or
more of the gynecological pathologies (endometriosis, adenomyosis, ovarian cysts,
fibroids, ovarian/cervical/uterine cancer) and asymptomatic females.
The patients concerned by the study will be managed without modification of the care
pathway, nor modification of the therapeutic indications, nor modification of the
diagnostic or follow-up examinations necessary according to the context, which are
carried out according to the local recommendations.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT GUSTAVE ROUSSY | Alexandra LEARY | 21/08/2026 13:25:02 | Contacter | ||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| American Hospital of Paris - Neuilly-sur-Seine - France | Sofiane Bendifallah, MD | Contact (sur clinicalTrials) | |||
| CGFL - Dijon - France | Hélène COSTAZ, Dr | Contact (sur clinicalTrials) | |||
| CHU Bretonneau-Tours - Tours - France | Lobna OULDAMER, Pr | Contact (sur clinicalTrials) | |||
| CHU Caen - 14033 - Caen - France | Raffaèle Fauvet, Pr | Contact (sur clinicalTrials) | |||
| CHU d'Angers - Angers - France | Léa DELBOS, Dr | Contact (sur clinicalTrials) | |||
| CHU de Rennes Site Hôpital Sud - Rennes - France | Vincent LAVOUE, Pr | Contact (sur clinicalTrials) | |||
| CHU Lyon Sud - Lyon - France | François GOLFIER, Pr | Contact (sur clinicalTrials) | |||
| CHU Rouen - Rouen - France | Morgane PERRIN, Dr | Contact (sur clinicalTrials) | |||
| Clinique La sagesse - Rennes - France | Claire Marie ROGER, Dr | Contact (sur clinicalTrials) | |||
| Clinique Pasteur - Toulouse - France | Ludivine Genre, Dr | Contact (sur clinicalTrials) | |||
| Clinique Tivoli Ducos - IFEMENDO - Bordeaux - France | Horace ROMAN, Pr | Contact (sur clinicalTrials) | |||
| Institut Bergonié - Bordeaux - France | Frédéric GUYON, Dr | Contact (sur clinicalTrials) | |||
| Institut Gustave Roussy - Villejuif - France | Alexandra LEARY, Dr | Contact (sur clinicalTrials) | |||
Critères
Femme
Inclusion Criteria:
1. Subject of legal age (according to local legislation) and at least 18 years old
2. Subject (and if applicable her legal representative) having dated and signed the
informed consent form
3. Subject with a medical insurance policy
4. Subject presenting to the department:
1. With Symptoms (bleeding and/or pain and/or clinically observed symptom) of one
or more of the following pathologies (suspected undergoing diagnostic
surgery/biopsy or diagnosed and before any curative treatment of the
pathology):
- Endometriosis
- Adenomyosis,
- Ovarian cysts,
- Fibroids,
- Ovarian cancer,
- Cervical cancer,
- Uterine cancer.
2. Asymptomatic with pap smear positive for cervical dysplasia or cervical cancer
and before any curative treatment.
3. Asymptomatic undergoing a pap smear for cervical cancer screening in a
gynecological follow-up context.
1. Subject of legal age (according to local legislation) and at least 18 years old
2. Subject (and if applicable her legal representative) having dated and signed the
informed consent form
3. Subject with a medical insurance policy
4. Subject presenting to the department:
1. With Symptoms (bleeding and/or pain and/or clinically observed symptom) of one
or more of the following pathologies (suspected undergoing diagnostic
surgery/biopsy or diagnosed and before any curative treatment of the
pathology):
- Endometriosis
- Adenomyosis,
- Ovarian cysts,
- Fibroids,
- Ovarian cancer,
- Cervical cancer,
- Uterine cancer.
2. Asymptomatic with pap smear positive for cervical dysplasia or cervical cancer
and before any curative treatment.
3. Asymptomatic undergoing a pap smear for cervical cancer screening in a
gynecological follow-up context.
1. Recent (<1 month) or ongoing bacterial or viral infection
2. Known active oral or digestive mycosis
3. Evolving oral pathology, symptomatic or obvious
4. Known pregnancy
5. Known current non-gynecological pelvic pathology
6. Subject with a diagnosed breast cancer or cancer other than gynecological with the
exception of basal cell carcinoma
7. Subject with a history of treated cancer within the last 5 years with the exception
of basal cell carcinoma
8. Subject who has already received chemotherapy or radiotherapy or undergone complete
or partial excision of the gynecological pathology of inclusion criterion
9. Subject with significant difficulties reading or writing her language
10. Subject unable to comply with study and/or follow-up procedures
11. Participation in an interventional study with investigational drug or in the
exclusion period of an interventional study.